GenSpera's G-202 Clinical Trial Advances to Phase Ib
3/29/2012 7:42:44 AM
SAN ANTONIO, Texas--(BUSINESS WIRE)--GenSpera, Inc. (OTCBB:GNSZ) announced the successful completion of the dose-escalation component in the ongoing Phase I trial of its lead chemotherapeutic agent, G-202. The trial will continue as a Phase Ib study evaluating G-202 in up to eighteen additional patients to further refine the dosing regimen and determine a recommended dose for Phase II clinical studies. Additionally, GenSpera expects to initiate its first Phase II study in castrate-resistant, chemotherapy-naïve prostate cancer patients within the next few months, also with G-202.